40 results on '"Helbig, I."'
Search Results
2. A SLC2A1 MUTATION IN A BOY WITH CHILDHOOD ABSENCE EPILEPSY, ALTERNATING HEMIPLEGIA AND ATAXIA: p818
- Author
-
Muhle, H., Möller, F., Stephani, U., and Helbig, I.
- Published
- 2012
3. AUTOSOMAL RECESSIVE PARTIAL EPILEPSY WITH INTELLECTUAL DISABILITY (ARPEID) - A NOVEL EPILEPSY SYNDROME?: p803
- Author
-
Afawi, Z., Abu-Rachma, J., Kivity, S., Blatt, I., and Helbig, I.
- Published
- 2012
4. DATA-DRIVEN PHENOMIC ANALYSIS OF EPILEPTIC ENCEPHALOPATHY PHENOTYPES USING AN ONTOLOGY-BASED PHENOTYPE DATABASE: p463
- Author
-
Albers, J. A., Weckhuysen, S., Suls, A., Coessens, B., Robinson, P. N., De Jonghe, P., Euroepinomics Res, C. R. P., and Helbig, I.
- Published
- 2012
5. LISTEN TO YOUR GENOME AND TALK TO YOUR PATIENTS: THE ARCHITECTURE OF THE HUMAN GENOME AND THE CHALLENGES OF PHENOTYPING
- Author
-
Helbig, I
- Published
- 2010
6. Exon-disrupting deletions ofNRXN1in idiopathic generalized epilepsy
- Author
-
Møller, R.S., Weber, Y.G., Klitten, L.L., Trucks, H., Muhle, H., Kunz, W.S., Mefford, H.C., Franke, A., Kautza, M., Wolf, P., Dennig, D., Schreiber, S., Rückert, I.M., Wichmann, H.E., Ernst, J.P., Schurmann, C., Grabe, H.J., Tommerup, N., Stephani, U., Lerche, H., Hjalgrim, H., Helbig, I., Sander, T., Zimprich, F., Mörzinger, M., Feucht, M., Suls, A., Weckhuysen, S., Claes, L., Deprez, L., Smets, K., Van Dyck, T., Deconinck, T., De Jonghe, P., Velizarova, R., Dimova, P., Radionova, M., Tournev, I., Kancheva, D., Kaneva, R., Jordanova, A., Kjelgaard, D.B., Lehesjoki, A.E., Siren, A., Baulac, S., Leguern, E., Von Spiczak, S., Ostertag, P., Leber, M., Leu, C., Toliat, M.R., Nürnberg, P., Hempelmann, A., Rüschendorf, F., Elger, C.E., Kleefuß Lie, A.A., Surges, R., Gaus, V., Janz, D., Schmitz, B., Klein, K.M., Reif, P.S., Oertel, W.H., Hamer, H.M., Rosenow, F., Becker, F., Marini, C., Guerrini, R., Mei, D., Norci, V., Zara, F., Striano, P., Robbiano, A., Pezzella, M., Bianchi, A., Gambardella, A., Tinuper, P., La Neve, A., Capovilla, G., Vigliano, P., Crichiutti, G., Vanadia, F., Vignoli, A., Coppola, A., Striano, S., Giallonardo, M.T., Franceschetti, S., Belcastro, V., Benna, P., Coppola, G., De Palo, A., Ferlazzo, E., Vecchi, M., Martinelli, V., Bisulli, F., Beccaria, F., Del Giudice, E., Mancardi, M., Stranci, G., Scabar, A., Gobbi, G., Giordano, I., Koeleman, B.P.C., De Kovel, C., Lindhout, D., De Haan, G.J., Ozbeck, U., Bebek, N., Baykan, B., Ozdemir, O., Ugur, S., Kocasoy Orhan, E., Yücesan, E., Cine, N., Gokyigit, A., Gurses, C., Gul, G., Yapici, Z., Ozkara, C., Caglayan, H., Yalcin, O., Yalcin, D., Turkdogan, D., Dizdarer, G., Agan, K., R. S. Møller, Y. G. Weber, L. L. Klitten, H. Truck, H. Muhle, W. S. Kunz, H. C. Mefford, A. Franke, M. Kautza, P. Wolf, D. Dennig, S. Schreiber, I. Rückert, H. Wichmann, J. P. Ernst, C. Schurmann, H. J. Grabe, N. Tommerup, U. Stephani, H. Lerche, H. Hjalgrim, I. Helbig, T. Sander, P. Tinuper, F. Bisulli, EPICURE Consortium, Suls, Arvid, Weckhuysen, Sarah, Claes, Godelieve, Deprez, Liesbet, Smets, Katrien, Van Dyck, Tine, Deconinck, Tine, De Jonghe, Peter, Jordanova, Albena, Møller, R, Weber, Yg, Klitten, Ll, Trucks, H, Muhle, H, Kunz, W, Mefford, Hc, Franke, A, Kautza, M, Wolf, P, Dennig, D, Schreiber, S, Rückert, Im, Wichmann, He, Ernst, Jp, Schurmann, C, Grabe, Hj, Tommerup, N, Stephani, U, Lerche, H, Hjalgrim, H, Helbig, I, Sander, T, Epicure, Consortium, DEL GIUDICE, Ennio, Coppola, Antonietta, and YÜCESAN, EMRAH
- Subjects
Male ,Idiopathic generalized epilepsy ,Neuronal ,Idiopathic Generalized Epilepsy ,1q21 ,1 Microdeletion ,Two-hit Hypothesis ,Nrxn1 ,Neuropsychological Tests ,Immunoglobulin E ,Cell Adhesion Molecules, Neuronal/genetics ,Adult, Age of Onset, Anticonvulsant ,Exon ,1q21.1 microdeletion ,Exons/genetics ,Odds Ratio ,Nerve Tissue Proteins/genetics ,Copy-number variation ,Valproic Acid/therapeutic use ,Age of Onset ,Neural Cell Adhesion Molecules ,genetics, DNA Copy Number Variations, Electroencephalography, Epilepsy ,Genetics ,biology ,Triazines ,Anticonvulsants/therapeutic use ,Electroencephalography ,genetics, Family, Female, Fructose ,Exons ,Middle Aged ,Settore MED/39 - Neuropsichiatria Infantile ,Pedigree ,therapeutic use, Valproic Acid ,Neurology ,Settore MED/26 - Neurologia ,Anticonvulsants ,Epilepsy, Generalized ,Female ,Adult ,Case-Control Studies ,Cell Adhesion Molecules, Neuronal ,DNA Copy Number Variations ,Family ,Fructose ,Gene Deletion ,Genotype ,Humans ,Infant ,Microarray Analysis ,Nerve Tissue Proteins ,Valproic Acid ,analogs /&/ derivatives/therapeutic use, Gene Deletion, Genotype, Humans, Infant, Male, Microarray Analysis, Middle Aged, Nerve Tissue Protein ,therapeutic use, Case-Control Studies, Cell Adhesion Molecule ,drug therapy/genetics/psychology, Exon ,genetics, Neuropsychological Tests, Odds Ratio, Pedigree, Triazine ,Lamotrigine ,NRXN1 ,Topiramate ,Epilepsy, Generalized/drug therapy ,medicine ,Allele ,Biology ,Gene ,Generalized ,Point mutation ,Calcium-Binding Proteins ,Odds ratio ,medicine.disease ,Triazines/therapeutic use ,Settore MED/03 - Genetica Medica ,therapeutic use ,biology.protein ,Fructose/analogs & derivatives ,Human medicine ,Neurology (clinical) ,Two-hit hypothesis - Abstract
Summary Purpose Neurexins are neuronal adhesion molecules located in the presynaptic terminal, where they interact with postsynaptic neuroligins to form a transsynaptic complex required for efficient neurotransmission in the brain. Recently, deletions and point mutations of the neurexin 1 (NRXN1) gene have been associated with a broad spectrum of neuropsychiatric disorders. This study aimed to investigate if NRXN1 deletions also increase the risk of idiopathic generalized epilepsies (IGEs). Methods We screened for deletions involving the NRXN1 gene in 1,569 patients with IGE and 6,201 controls using high-density oligonucleotide microarrays. Key Findings We identified exon-disrupting deletions of NRXN1 in 5 of 1,569 patients with IGE and 2 of 6,201 control individuals (p = 0.0049; odds ratio (OR) 9.91, 95% confidence interval (CI) 1.92–51.12). A complex familial segregation pattern in the IGE families was observed, suggesting that heterozygous NRXN1 deletions are susceptibility variants. Intriguingly, we identified a second large copy number variant in three of five index patients, supporting an involvement of heterogeneous susceptibility alleles in the etiology of IGE. Significance We conclude that exon-disrupting deletions of NRXN1 represent a genetic risk factor in the genetically complex predisposition of common IGE syndromes.
- Published
- 2013
7. Gene expression analysis in absence epilepsy using a monozygotic twin design
- Author
-
Samuel F. Berkovic, Dileepa Diyagama, Leanne M. Dibbens, Andrew J. Holloway, Ingo Helbig, Lata Vadlamudi, Marta A. Bayly, Nicholas Matigian, Sharon M. Bain, Ingrid E. Scheffer, Nicholas K. Hayward, Kate M. Lawrence, John C. Mulley, Helbig, I, Matigian, N.A, Vadlamudi, L, Bayly, Marta Anna, Bain, M.A, Diyagama, D, Scheffer, Ingrid, Mulley, John, Holloway, A.J, Dibbens, Leanne Michelle, Berkovic, Sam, and Hayward, NK
- Subjects
Adult ,Male ,Clinical Sciences ,Gene Expression ,Monozygotic twin ,Epilepsy ,Cell Line, Tumor ,Gene expression ,medicine ,Humans ,twin study ,Gene ,Early Growth Response Protein 1 ,Oligonucleotide Array Sequence Analysis ,Genetics ,Reverse Transcriptase Polymerase Chain Reaction ,Microarray analysis techniques ,Valproic Acid ,Calcium-Binding Proteins ,Twins, Monozygotic ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Twin study ,Absence seizure ,Epilepsy, Absence ,Neurology ,gene expression ,epilepsy ,Anticonvulsants ,Female ,Neurology (clinical) ,Juvenile myoclonic epilepsy ,Psychology ,absence seizure - Abstract
To identify genes involved in idiopathic absence epilepsies by analyzing gene expression using a monozygotic (MZ) twin design.Genome-wide gene expression in lymphoblastoid cell lines (LCLs) was determined using microarrays derived from five discordant and four concordant MZ twin pairs with idiopathic absence epilepsies and five unaffected MZ twin pairs. Gene expression was analyzed using three strategies: discordant MZ twins were compared as matched pairs, MZ twins concordant for epilepsy were compared to control MZ twins, and a singleton design of affected versus unaffected MZ twin individuals was used irrespective of twin pairing. An overlapping gene list was generated from these analyses. Dysregulation of genes recognized from the microarray experiment was validated using quantitative real time PCR (qRT-PCR) in the twin sample and in an independent sample of 18 sporadic absence cases and 24 healthy controls.Sixty-five probe sets were identified from the three combined microarray analysis strategies. Sixteen genes were chosen for validation and nine of these genes confirmed by qRT-PCR in the twin sample. Differential expression for EGR1 (an immediate early gene) and RCN2 (coding for the calcium-binding protein Reticulocalbin 2) were reconfirmed by qRT-PCR in the independent sample.Using a unique sample of discordant MZ twins, our study identified genes with altered expression, which suggests novel mechanisms in idiopathic absence epilepsy. Dysregulation of EGR1 and RCN2 is implicated in idiopathic absence epilepsy.
- Published
- 2008
8. Early life seizures and epileptic spasms in STXBP1-related disorders.
- Author
-
Thalwitzer KM, Xian J, de Campo D, Parthasarathy S, Magielski J, Sullivan KR, Goss J, Rigby CS, Boland M, Prosser B, Ruggiero SM, Syrbe S, and Helbig I
- Subjects
- Infant, Newborn, Humans, Infant, Retrospective Studies, Electroencephalography, Seizures genetics, Seizures drug therapy, Spasm, Munc18 Proteins genetics, Spasms, Infantile genetics, Spasms, Infantile drug therapy, Epilepsy complications, Epilepsy drug therapy, Epilepsy genetics
- Abstract
Objective: Individuals with disease-causing variants in STXBP1 frequently have epilepsy onset in the first year of life with a variety of seizure types, including epileptic spasms. However, the impact of early onset seizures and antiseizure medication (ASM) on the risk of developing epileptic spasms and impact on their trajectory are poorly understood, limiting informed and anticipatory treatment, as well as trial design., Methods: We retrospectively reconstructed seizure and medication histories in weekly intervals for individuals with STXBP1 developmental and epileptic encephalopathy (DEE) with epilepsy onset in the first year of life and quantitatively analyzed longitudinal seizure histories and medication response., Results: We included 61 individuals with early onset seizures, 29 of whom had epileptic spasms. Individuals with neonatal seizures were likely to have continued seizures after the neonatal period (25/26). The risk of developing epileptic spasms was not increased in individuals with neonatal seizures or early infantile seizures (21/41 vs. 8/16, odds ratio [OR] = 1, 95% confidence interval [CI] = .3-3.9, p = 1). We did not find any ASM associated with the development of epileptic spasms following prior seizures. Individuals with prior seizures (n = 16/21, 76%) had a higher risk of developing refractory epileptic spasms (n = 5/8, 63%, OR = 1.9, 95% CI = .2-14.6, p = .6). Individuals with refractory epileptic spasms had a later onset of epileptic spasms (n = 20, median = 20 weeks) compared to individuals with nonrefractory epileptic spasms (n = 8, median = 13 weeks, p = .08)., Significance: We provide a comprehensive assessment of early onset seizures in STXBP1-DEE and show that the risk of epileptic spasms is not increased following a prior history of early life seizures, nor by certain ASMs. Our study provides baseline information for targeted treatment and prognostication in early life seizures in STXBP1-DEE., (© 2024 International League Against Epilepsy.)
- Published
- 2024
- Full Text
- View/download PDF
9. A quality improvement initiative to improve folic acid supplementation counseling for adolescent females with epilepsy.
- Author
-
Molisani SE, Parikh D, DiGiovine M, Dlugos D, Fitzgerald MP, Fried L, Helbig I, Kessler SK, McDonnell PP, Melamed S, Prelack MS, Sharif U, Tefft S, Tencer J, Witzman S, Shaw K, and Abend NS
- Abstract
Objective: We designed a quality improvement (QI) project to improve rates of documented folic acid supplementation counseling for adolescent females with epilepsy, consistent with a quality measure from the American Academy of Neurology and American Epilepsy Society. Our SMART aim was to increase the percentage of visits at which folic acid counseling was addressed from our baseline rate of 23% to 50% by July 1, 2020., Methods: This initiative was conducted in female patients ≥12 years old with epilepsy who were prescribed daily antiseizure medication and were seen by the 13 providers in our Neurology QI Program. Using provider interviews, we undertook a root cause analysis of low counseling rates and identified the following main factors: insufficient time during clinic visit to counsel, lack of provider knowledge, and forgetting to counsel. Countermeasures were designed to address these main root causes and were implemented through iterative plan-do-study-act (PDSA) cycles. Interventions included provider education and features within the electronic health record, which were introduced sequentially, culminating in the creation of a best practice advisory (BPA). We performed biweekly chart reviews of visits for applicable patients to establish baseline performance rate and track progress over time. We used a statistical process control p-chart to analyze the outcome measure of documented counseling. As a balancing measure, clinicians were surveyed using the Technology Adoption Model survey to assess acceptance of the BPA., Results: From September 2019 to August 2022, the QI team improved rates of documented folic acid counseling from 23% to 73% through several PDSA cycles. This level of performance has been sustained over time. The most successful and sustainable intervention was the BPA. Provider acceptance of the BPA was overall positive., Significance: We successfully used QI methodology to improve and sustain our rates of documented folic acid supplementation counseling for adolescent females with epilepsy., (© 2023 International League Against Epilepsy.)
- Published
- 2023
- Full Text
- View/download PDF
10. Review and standard operating procedures for collection of biospecimens and analysis of biomarkers in new onset refractory status epilepticus.
- Author
-
Hanin A, Cespedes J, Pulluru Y, Gopaul M, Aronica E, Decampo D, Helbig I, Howe CL, Huttner A, Koh S, Navarro V, Taraschenko O, Vezzani A, Wilson MR, Xian J, Gaspard N, and Hirsch LJ
- Subjects
- Humans, Biological Specimen Banks, Seizures complications, Biomarkers, Status Epilepticus drug therapy, Drug Resistant Epilepsy therapy, Encephalitis complications
- Abstract
New onset refractory status epilepticus (NORSE), including its subtype with a preceding febrile illness known as febrile infection-related epilepsy syndrome (FIRES), is one of the most severe forms of status epilepticus. The exact causes of NORSE are currently unknown, and there is so far no disease-specific therapy. Identifying the underlying pathophysiology and discovering specific biomarkers, whether immunologic, infectious, genetic, or other, may help physicians in the management of patients with NORSE. A broad spectrum of biomarkers has been proposed for status epilepticus patients, some of which were evaluated for patients with NORSE. Nonetheless, none has been validated, due to significant variabilities in study cohorts, collected biospecimens, applied analytical methods, and defined outcome endpoints, and to small sample sizes. The NORSE Institute established an open NORSE/FIRES biorepository for health-related data and biological samples allowing the collection of biospecimens worldwide, promoting multicenter research and sharing of data and specimens. Here, we suggest standard operating procedures for biospecimen collection and biobanking in this rare condition. We also propose criteria for the appropriate use of previously collected biospecimens. We predict that the widespread use of standardized procedures will reduce heterogeneity, facilitate the future identification of validated biomarkers for NORSE, and provide a better understanding of the pathophysiology and best clinical management for these patients., (© 2023 International League Against Epilepsy.)
- Published
- 2023
- Full Text
- View/download PDF
11. SCN1A gain-of-function mutation causing an early onset epileptic encephalopathy.
- Author
-
Clatot J, Parthasarathy S, Cohen S, McKee JL, Massey S, Somarowthu A, Goldberg EM, and Helbig I
- Subjects
- Humans, Infant, Newborn, Gain of Function Mutation genetics, HEK293 Cells, Mutation genetics, Oxcarbazepine, Epilepsies, Myoclonic genetics, Epilepsy genetics, NAV1.1 Voltage-Gated Sodium Channel genetics
- Abstract
Objective: Loss-of-function variants in SCN1A cause Dravet syndrome, the most common genetic developmental and epileptic encephalopathy (DEE). However, emerging evidence suggests separate entities of SCN1A-related disorders due to gain-of-function variants. Here, we aim to refine the clinical, genetic, and functional electrophysiological features of a recurrent p.R1636Q gain-of-function variant, identified in four individuals at a single center., Methods: Individuals carrying the recurrent SCN1A p.R1636Q variant were identified through diagnostic testing. Whole cell voltage-clamp electrophysiological recording in HEK-293 T cells was performed to compare the properties of sodium channels containing wild-type Na
v 1.1 or Nav 1.1-R1636Q along with both Nav β1 and Nav β2 subunits, including response to oxcarbazepine. To delineate differences from other SCN1A-related epilepsies, we analyzed electronic medical records., Results: All four individuals had an early onset DEE characterized by focal tonic seizures and additional seizure types starting in the first few weeks of life. Electrophysiological analysis showed a mixed gain-of-function effect with normal current density, a leftward (hyperpolarized) shift of steady-state inactivation, and slower inactivation kinetics leading to a prominent late sodium current. The observed functional changes closely paralleled effects of pathogenic variants in SCN3A and SCN8A at corresponding positions. Both wild type and variant exhibited sensitivity to block by oxcarbazepine, partially correcting electrophysiological abnormalities of the SCN1A p.R1636Q variant. Clinically, a single individual responded to treatment with oxcarbazepine. Across 51 individuals with SCN1A-related epilepsies, those with the recurrent p.R1636Q variants had the earliest ages at onset., Significance: The recurrent SCN1A p.R1636Q variant causes a clinical entity with a wider clinical spectrum than previously reported, characterized by neonatal onset epilepsy and absence of prominent movement disorder. Functional consequences of this variant lead to mixed loss and gain of function that is partially corrected by oxcarbazepine. The recurrent p.R1636Q variant represents one of the most common causes of early onset SCN1A-related epilepsies with separate treatment and prognosis implications., (© 2022 International League Against Epilepsy.)- Published
- 2023
- Full Text
- View/download PDF
12. Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress.
- Author
-
Knowles JK, Helbig I, Metcalf CS, Lubbers LS, Isom LL, Demarest S, Goldberg EM, George AL Jr, Lerche H, Weckhuysen S, Whittemore V, Berkovic SF, and Lowenstein DH
- Subjects
- Genetic Testing, Humans, Seizures genetics, Suggestion, Epilepsy diagnosis, Epilepsy genetics, Epilepsy therapy, Precision Medicine
- Abstract
The genetic basis of many epilepsies is increasingly understood, giving rise to the possibility of precision treatments tailored to specific genetic etiologies. Despite this, current medical therapy for most epilepsies remains imprecise, aimed primarily at empirical seizure reduction rather than targeting specific disease processes. Intellectual and technological leaps in diagnosis over the past 10 years have not yet translated to routine changes in clinical practice. However, the epilepsy community is poised to make impressive gains in precision therapy, with continued innovation in gene discovery, diagnostic ability, and bioinformatics; increased access to genetic testing and counseling; fuller understanding of natural histories; agility and rigor in preclinical research, including strategic use of emerging model systems; and engagement of an evolving group of stakeholders (including patient advocates, governmental resources, and clinicians and scientists in academia and industry). In each of these areas, we highlight notable examples of recent progress, new or persistent challenges, and future directions. The future of precision medicine for genetic epilepsy looks bright if key opportunities on the horizon can be pursued with strategic and coordinated effort., (© 2022 International League Against Epilepsy.)
- Published
- 2022
- Full Text
- View/download PDF
13. Whole exome sequencing and co-expression analysis identify an SCN1A variant that modifies pathogenicity in a family with genetic epilepsy and febrile seizures plus.
- Author
-
Hammer MF, Pan Y, Cumbay M, Pendziwiat M, Afawi Z, Goldberg-Stern H, Johnstone L, Helbig I, and Cummins TR
- Subjects
- HEK293 Cells, Humans, Mutation, NAV1.1 Voltage-Gated Sodium Channel genetics, Phenotype, Virulence, Exome Sequencing, Epilepsies, Myoclonic genetics, Epilepsy complications, Epilepsy genetics, Seizures, Febrile complications, Seizures, Febrile genetics
- Abstract
Objective: Family members carrying the same SCN1A variant often exhibit differences in the clinical severity of epilepsy. This variable expressivity suggests that other factors aside from the primary sodium channel variant influence the clinical manifestation. However, identifying such factors has proven challenging in humans., Methods: We perform whole exome sequencing (WES) in a large family in which an SCN1A variant (p.K1372E) is segregating that is associated with a broad spectrum of phenotypes ranging from lack of epilepsy, to febrile seizures and absence seizures, to Dravet syndrome. We assessed the hypothesis that the severity of the SCN1A-related phenotype was affected by alternate alleles at a modifier locus (or loci)., Results: One of our top candidates identified by WES was a second variant in the SCN1A gene (p.L375S) that was shared exclusively by unaffected carriers of the K1372E allele. To test the hypothesized that L375S variant nullifies the loss-of-function effect of K1372E, we transiently expressed Nav1.1 carrying the two variants in HEK293T cells and compared their biophysical properties with the wild-type (WT) variant, and then co-expressed WT with K1372E or L375S with K1372E in equal quantity and tested the functional consequence. The data demonstrated that co-expression of the L375S and K1372E alleles reversed the loss-of-function property brought by the K1372E variant, whereas WT-K1372E co-expression remained partial loss-of-function., Significance: These results support the hypothesis that L375S counteracts the loss-of-function effect of K1372E such that individuals carrying both alleles in trans do not present epilepsy-related symptoms. We demonstrate that monogenic epilepsies with wide expressivity can be modified by additional variants in the disease gene, providing a novel framework for the gene-phenotype relationship in genetic epilepsies., (© 2022 International League Against Epilepsy.)
- Published
- 2022
- Full Text
- View/download PDF
14. Assessing seizure burden in pediatric epilepsy using an electronic medical record-based tool through a common data element approach.
- Author
-
Fitzgerald MP, Kaufman MC, Massey SL, Fridinger S, Prelack M, Ellis C, Ortiz-Gonzalez X, Fried LE, DiGiovine MP, Melamed S, Malcolm M, Banwell B, Stephenson D, Witzman SM, Gonzalez A, Dlugos D, Kessler SK, Goldberg EM, Abend NS, and Helbig I
- Subjects
- Adolescent, Anticonvulsants therapeutic use, Child, Child, Preschool, Common Data Elements, Epilepsies, Myoclonic epidemiology, Epilepsy, Absence epidemiology, Female, Hispanic or Latino, Humans, Lennox Gastaut Syndrome epidemiology, Male, Seizures epidemiology, Socioeconomic Factors, Telemedicine, Treatment Outcome, Cost of Illness, Electronic Health Records, Epilepsy economics
- Abstract
Objective: Improvement in epilepsy care requires standardized methods to assess disease severity. We report the results of implementing common data elements (CDEs) to document epilepsy history data in the electronic medical record (EMR) after 12 months of clinical use in outpatient encounters., Methods: Data regarding seizure frequency were collected during routine clinical encounters using a CDE-based form within our EMR. We extracted CDE data from the EMR and developed measurements for seizure severity and seizure improvement scores. Seizure burden and improvement was evaluated by patient demographic and encounter variables for in-person and telemedicine encounters., Results: We assessed a total of 1696 encounters in 1038 individuals with childhood epilepsies between September 6, 2019 and September 11, 2020 contributed by 32 distinct providers. Childhood absence epilepsy (n = 121), Lennox-Gastaut syndrome (n = 86), and Dravet syndrome (n = 42) were the most common epilepsy syndromes. Overall, 43% (737/1696) of individuals had at least monthly seizures, 17% (296/1696) had a least daily seizures, and 18% (311/1696) were seizure-free for >12 months. Quantification of absolute seizure burden and changes in seizure burden over time differed between epilepsy syndromes, including high and persistent seizure burden in patients with Lennox-Gastaut syndrome. Individuals seen via telemedicine or in-person encounters had comparable seizure frequencies. Individuals identifying as Hispanic/Latino, particularly from postal codes with lower median household incomes, were more likely to have ongoing seizures that worsened over time., Significance: Standardized documentation of clinical data in childhood epilepsies through CDE can be implemented in routine clinical care at scale and enables assessment of disease burden, including characterization of seizure burden over time. Our data provide insights into heterogeneous patterns of seizure control in common pediatric epilepsy syndromes and will inform future initiatives focusing on patient-centered outcomes in childhood epilepsies, including the impact of telemedicine and health care disparities., (© 2021 International League Against Epilepsy.)
- Published
- 2021
- Full Text
- View/download PDF
15. Modeling seizures in the Human Phenotype Ontology according to contemporary ILAE concepts makes big phenotypic data tractable.
- Author
-
Lewis-Smith D, Galer PD, Balagura G, Kearney H, Ganesan S, Cosico M, O'Brien M, Vaidiswaran P, Krause R, Ellis CA, Thomas RH, Robinson PN, and Helbig I
- Subjects
- Big Data, Cohort Studies, Data Interpretation, Statistical, Epilepsies, Partial classification, Epilepsies, Partial physiopathology, Epilepsy, Epilepsy, Generalized classification, Epilepsy, Generalized physiopathology, Epilepsy, Tonic-Clonic classification, Epilepsy, Tonic-Clonic physiopathology, Genomics, High-Throughput Nucleotide Sequencing, Humans, Phenotype, Seizures classification, Seizures genetics, Models, Neurological, Seizures physiopathology
- Abstract
Objective: The clinical features of epilepsy determine how it is defined, which in turn guides management. Therefore, consideration of the fundamental clinical entities that comprise an epilepsy is essential in the study of causes, trajectories, and treatment responses. The Human Phenotype Ontology (HPO) is used widely in clinical and research genetics for concise communication and modeling of clinical features, allowing extracted data to be harmonized using logical inference. We sought to redesign the HPO seizure subontology to improve its consistency with current epileptological concepts, supporting the use of large clinical data sets in high-throughput clinical and research genomics., Methods: We created a new HPO seizure subontology based on the 2017 International League Against Epilepsy (ILAE) Operational Classification of Seizure Types, and integrated concepts of status epilepticus, febrile, reflex, and neonatal seizures at different levels of detail. We compared the HPO seizure subontology prior to, and following, our revision, according to the information that could be inferred about the seizures of 791 individuals from three independent cohorts: 2 previously published and 150 newly recruited individuals. Each cohort's data were provided in a different format and harmonized using the two versions of the HPO., Results: The new seizure subontology increased the number of descriptive concepts for seizures 5-fold. The number of seizure descriptors that could be annotated to the cohort increased by 40% and the total amount of information about individuals' seizures increased by 38%. The most important qualitative difference was the relationship of focal to bilateral tonic-clonic seizure to generalized-onset and focal-onset seizures., Significance: We have generated a detailed contemporary conceptual map for harmonization of clinical seizure data, implemented in the official 2020-12-07 HPO release and freely available at hpo.jax.org. This will help to overcome the phenotypic bottleneck in genomics, facilitate reuse of valuable data, and ultimately improve diagnostics and precision treatment of the epilepsies., (© 2021 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)
- Published
- 2021
- Full Text
- View/download PDF
16. Design and implementation of electronic health record common data elements for pediatric epilepsy: Foundations for a learning health care system.
- Author
-
Grinspan ZM, Patel AD, Shellhaas RA, Berg AT, Axeen ET, Bolton J, Clarke DF, Coryell J, Gaillard WD, Goodkin HP, Koh S, Kukla A, Mbwana JS, Morgan LA, Singhal NS, Storey MM, Yozawitz EG, Abend NS, Fitzgerald MP, Fridinger SE, Helbig I, Massey SL, Prelack MS, and Buchhalter J
- Subjects
- Comparative Effectiveness Research, Epidemiological Monitoring, Health Services Research, Humans, Implementation Science, Outcome and Process Assessment, Health Care, Quality Improvement, Common Data Elements, Electronic Health Records, Epilepsy diagnosis, Epilepsy physiopathology, Epilepsy therapy, Neurology, Pediatrics
- Abstract
Objective: Common data elements (CDEs) are standardized questions and answer choices that allow aggregation, analysis, and comparison of observations from multiple sources. Clinical CDEs are foundational for learning health care systems, a data-driven approach to health care focused on continuous improvement of outcomes. We aimed to create clinical CDEs for pediatric epilepsy., Methods: A multiple stakeholder group (clinicians, researchers, parents, caregivers, advocates, and electronic health record [EHR] vendors) developed clinical CDEs for routine care of children with epilepsy. Initial drafts drew from clinical epilepsy note templates, CDEs created for clinical research, items in existing registries, consensus documents and guidelines, quality metrics, and outcomes needed for demonstration projects. The CDEs were refined through discussion and field testing. We describe the development process, rationale for CDE selection, findings from piloting, and the CDEs themselves. We also describe early implementation, including experience with EHR systems and compatibility with the International League Against Epilepsy classification of seizure types., Results: Common data elements were drafted in August 2017 and finalized in January 2020. Prioritized outcomes included seizure control, seizure freedom, American Academy of Neurology quality measures, presence of common comorbidities, and quality of life. The CDEs were piloted at 224 visits at 10 centers. The final CDEs included 36 questions in nine sections (number of questions): diagnosis (1), seizure frequency (9), quality of life (2), epilepsy history (6), etiology (8), comorbidities (2), treatment (2), process measures (5), and longitudinal history notes (1). Seizures are categorized as generalized tonic-clonic (regardless of onset), motor, nonmotor, and epileptic spasms. Focality is collected as epilepsy type rather than seizure type. Seizure frequency is measured in nine levels (all used during piloting). The CDEs were implemented in three vendor systems. Early clinical adoption included 1294 encounters at one center., Significance: We created, piloted, refined, finalized, and implemented a novel set of clinical CDEs for pediatric epilepsy., (© 2020 International League Against Epilepsy.)
- Published
- 2021
- Full Text
- View/download PDF
17. Lessons learned from 40 novel PIGA patients and a review of the literature.
- Author
-
Bayat A, Knaus A, Pendziwiat M, Afenjar A, Barakat TS, Bosch F, Callewaert B, Calvas P, Ceulemans B, Chassaing N, Depienne C, Endziniene M, Ferreira CR, Moura de Souza CF, Freihuber C, Ganesan S, Gataullina S, Guerrini R, Guerrot AM, Hansen L, Jezela-Stanek A, Karsenty C, Kievit A, Kooy FR, Korff CM, Kragh Hansen J, Larsen M, Layet V, Lesca G, McBride KL, Meuwissen M, Mignot C, Montomoli M, Moore H, Naudion S, Nava C, Nougues MC, Parrini E, Pastore M, Schelhaas JH, Skinner S, Szczałuba K, Thomas A, Thomassen M, Tranebjaerg L, van Slegtenhorst M, Wolfe LA, Lal D, Gardella E, Bomme Ousager L, Brünger T, Helbig I, Krawitz P, and Møller RS
- Subjects
- Adult, Amino Acid Sequence, Child, Cohort Studies, Electroencephalography methods, Facies, Hernia, Diaphragmatic physiopathology, Humans, Infant, Newborn, Limb Deformities, Congenital physiopathology, Magnetic Resonance Imaging methods, Male, Genetic Variation genetics, Hernia, Diaphragmatic diagnostic imaging, Hernia, Diaphragmatic genetics, Limb Deformities, Congenital diagnostic imaging, Limb Deformities, Congenital genetics, Membrane Proteins genetics
- Abstract
Objective: To define the phenotypic spectrum of phosphatidylinositol glycan class A protein (PIGA)-related congenital disorder of glycosylation (PIGA-CDG) and evaluate genotype-phenotype correlations., Methods: Our cohort encompasses 40 affected males with a pathogenic PIGA variant. We performed a detailed phenotypic assessment, and in addition, we reviewed the available clinical data of 36 previously published cases and assessed the variant pathogenicity using bioinformatical approaches., Results: Most individuals had hypotonia, moderate to profound global developmental delay, and intractable seizures. We found that PIGA-CDG spans from a pure neurological phenotype at the mild end to a Fryns syndrome-like phenotype. We found a high frequency of cardiac anomalies including structural anomalies and cardiomyopathy, and a high frequency of spontaneous death, especially in childhood. Comparative bioinformatical analysis of common variants, found in the healthy population, and pathogenic variants, identified in affected individuals, revealed a profound physiochemical dissimilarity of the substituted amino acids in variant constrained regions of the protein., Significance: Our comprehensive analysis of the largest cohort of published and novel PIGA patients broadens the spectrum of PIGA-CDG. Our genotype-phenotype correlation facilitates the estimation on pathogenicity of variants with unknown clinical significance and prognosis for individuals with pathogenic variants in PIGA., (© 2020 International League Against Epilepsy.)
- Published
- 2020
- Full Text
- View/download PDF
18. Phenotypic and genetic spectrum of epilepsy with myoclonic atonic seizures.
- Author
-
Tang S, Addis L, Smith A, Topp SD, Pendziwiat M, Mei D, Parker A, Agrawal S, Hughes E, Lascelles K, Williams RE, Fallon P, Robinson R, Cross HJ, Hedderly T, Eltze C, Kerr T, Desurkar A, Hussain N, Kinali M, Bagnasco I, Vassallo G, Whitehouse W, Goyal S, Absoud M, Møller RS, Helbig I, Weber YG, Marini C, Guerrini R, Simpson MA, and Pal DK
- Subjects
- Age of Onset, Attention Deficit Disorder with Hyperactivity complications, Attention Deficit Disorder with Hyperactivity genetics, Attention Deficit Disorder with Hyperactivity pathology, Autism Spectrum Disorder complications, Autism Spectrum Disorder genetics, Autism Spectrum Disorder pathology, Child, Child, Preschool, Electroencephalography, Epilepsies, Myoclonic complications, Epilepsies, Myoclonic genetics, Epilepsy, Generalized complications, Epilepsy, Generalized genetics, Female, Humans, Infant, Intellectual Disability complications, Intellectual Disability genetics, Intellectual Disability pathology, Male, Neuroimaging, Phenotype, Seizures genetics, Exome Sequencing, Epilepsies, Myoclonic pathology, Epilepsy, Generalized pathology, Seizures pathology
- Abstract
Objective: We aimed to describe the extent of neurodevelopmental impairments and identify the genetic etiologies in a large cohort of patients with epilepsy with myoclonic atonic seizures (MAE)., Methods: We deeply phenotyped MAE patients for epilepsy features, intellectual disability, autism spectrum disorder, and attention-deficit/hyperactivity disorder using standardized neuropsychological instruments. We performed exome analysis (whole exome sequencing) filtered on epilepsy and neuropsychiatric gene sets to identify genetic etiologies., Results: We analyzed 101 patients with MAE (70% male). The median age of seizure onset was 34 months (range = 6-72 months). The main seizure types were myoclonic atonic or atonic in 100%, generalized tonic-clonic in 72%, myoclonic in 69%, absence in 60%, and tonic seizures in 19% of patients. We observed intellectual disability in 62% of patients, with extremely low adaptive behavioral scores in 69%. In addition, 24% exhibited symptoms of autism and 37% exhibited attention-deficit/hyperactivity symptoms. We discovered pathogenic variants in 12 (14%) of 85 patients, including five previously published patients. These were pathogenic genetic variants in SYNGAP1 (n = 3), KIAA2022 (n = 2), and SLC6A1 (n = 2), as well as KCNA2, SCN2A, STX1B, KCNB1, and MECP2 (n = 1 each). We also identified three new candidate genes, ASH1L, CHD4, and SMARCA2 in one patient each., Significance: MAE is associated with significant neurodevelopmental impairment. MAE is genetically heterogeneous, and we identified a pathogenic genetic etiology in 14% of this cohort by exome analysis. These findings suggest that MAE is a manifestation of several etiologies rather than a discrete syndromic entity., (© 2020 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)
- Published
- 2020
- Full Text
- View/download PDF
19. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice.
- Author
-
Brunklaus A, Du J, Steckler F, Ghanty II, Johannesen KM, Fenger CD, Schorge S, Baez-Nieto D, Wang HR, Allen A, Pan JQ, Lerche H, Heyne H, Symonds JD, Zuberi SM, Sanders S, Sheidley BR, Craiu D, Olson HE, Weckhuysen S, DeJonge P, Helbig I, Van Esch H, Busa T, Milh M, Isidor B, Depienne C, Poduri A, Campbell AJ, Dimidschstein J, Møller RS, and Lal D
- Subjects
- Age of Onset, Autism Spectrum Disorder genetics, Autism Spectrum Disorder physiopathology, Child, Child, Preschool, Codon, Nonsense, DNA Copy Number Variations, Electroencephalography, Epileptic Syndromes drug therapy, Epileptic Syndromes physiopathology, Female, Gain of Function Mutation, Gene Deletion, Gene Duplication, Gene Expression, Gene Expression Regulation, Developmental, Genotype, Humans, Infant, Infant, Newborn, Loss of Function Mutation, Male, Mutation, Missense, NAV1.1 Voltage-Gated Sodium Channel metabolism, NAV1.2 Voltage-Gated Sodium Channel metabolism, NAV1.3 Voltage-Gated Sodium Channel metabolism, NAV1.6 Voltage-Gated Sodium Channel metabolism, Neurodevelopmental Disorders genetics, Neurodevelopmental Disorders physiopathology, Phenotype, Sodium Channel Blockers therapeutic use, Sodium Channels metabolism, Epileptic Syndromes genetics, NAV1.1 Voltage-Gated Sodium Channel genetics, NAV1.2 Voltage-Gated Sodium Channel genetics, NAV1.3 Voltage-Gated Sodium Channel genetics, NAV1.6 Voltage-Gated Sodium Channel genetics, Sodium Channels genetics
- Abstract
Objective: Voltage-gated sodium channels (SCNs) share similar amino acid sequence, structure, and function. Genetic variants in the four human brain-expressed SCN genes SCN1A/2A/3A/8A have been associated with heterogeneous epilepsy phenotypes and neurodevelopmental disorders. To better understand the biology of seizure susceptibility in SCN-related epilepsies, our aim was to determine similarities and differences between sodium channel disorders, allowing us to develop a broader perspective on precision treatment than on an individual gene level alone., Methods: We analyzed genotype-phenotype correlations in large SCN-patient cohorts and applied variant constraint analysis to identify severe sodium channel disease. We examined temporal patterns of human SCN expression and correlated functional data from in vitro studies with clinical phenotypes across different sodium channel disorders., Results: Comparing 865 epilepsy patients (504 SCN1A, 140 SCN2A, 171 SCN8A, four SCN3A, 46 copy number variation [CNV] cases) and analysis of 114 functional studies allowed us to identify common patterns of presentation. All four epilepsy-associated SCN genes demonstrated significant constraint in both protein truncating and missense variation when compared to other SCN genes. We observed that age at seizure onset is related to SCN gene expression over time. Individuals with gain-of-function SCN2A/3A/8A missense variants or CNV duplications share similar characteristics, most frequently present with early onset epilepsy (<3 months), and demonstrate good response to sodium channel blockers (SCBs). Direct comparison of corresponding SCN variants across different SCN subtypes illustrates that the functional effects of variants in corresponding channel locations are similar; however, their clinical manifestation differs, depending on their role in different types of neurons in which they are expressed., Significance: Variant function and location within one channel can serve as a surrogate for variant effects across related sodium channels. Taking a broader view on precision treatment suggests that in those patients with a suspected underlying genetic epilepsy presenting with neonatal or early onset seizures (<3 months), SCBs should be considered., (Wiley Periodicals, Inc. © 2020 International League Against Epilepsy.)
- Published
- 2020
- Full Text
- View/download PDF
20. Inclusion of hemimegalencephaly into the phenotypic spectrum of NPRL3 pathogenic variants in familial focal epilepsy with variable foci.
- Author
-
Canavati C, Klein KM, Afawi Z, Pendziwiat M, Abu Rayyan A, Kamal L, Zahdeh F, Qaysia I, Helbig I, and Kanaan M
- Subjects
- Adolescent, Adult, Age of Onset, Apoptosis Regulatory Proteins genetics, Child, Child, Preschool, Developmental Disabilities etiology, Developmental Disabilities genetics, Epilepsy, Frontal Lobe complications, Epilepsy, Frontal Lobe genetics, Exome genetics, Family, Female, Gene Deletion, Genetic Variation, Genotype, Humans, Infant, Male, Membrane Proteins genetics, Pedigree, Polymorphism, Single Nucleotide genetics, Proto-Oncogene Proteins genetics, Epilepsies, Partial complications, Epilepsies, Partial genetics, GTPase-Activating Proteins genetics, Megalencephaly etiology, Megalencephaly genetics
- Abstract
Despite tremendous progress through next generation sequencing technologies, familial focal epilepsies are insufficiently understood. We sought to identify the genetic basis in multiplex Palestinian families with familial focal epilepsy with variable foci (FFEVF). Family I with 10 affected individuals and Family II with five affected individuals underwent detailed phenotyping over three generations. The phenotypic spectrum of the two families varied from nonlesional focal epilepsy including nocturnal frontal lobe epilepsy to severe structural epilepsy due to hemimegalencephaly. Whole-exome sequencing and single nucleotide polymorphism array analysis revealed pathogenic variants in NPRL3 in each family, a partial ~38-kb deletion encompassing eight exons (exons 8-15) and the 3'-untranslated region of the NPRL3 gene in Family I, and a de novo nonsense variant c.1063C>T, p.Gln355* in Family II. Furthermore, we identified a truncating variant in the PDCD10 gene in addition to the NPRL3 variant in a patient with focal epilepsy from Family I. The individual also had developmental delay and multiple cerebral cavernomas, possibly demonstrating a digenic contribution to the individual's phenotype. Our results implicate the association of NPRL3 with hemimegalencephaly, expanding the phenotypic spectrum of NPRL3 in FFEVF and underlining that partial deletions are part of the genotypic spectrum of NPRL3 variants., (Wiley Periodicals, Inc. © 2019 International League Against Epilepsy.)
- Published
- 2019
- Full Text
- View/download PDF
21. The spectrum of intermediate SCN8A-related epilepsy.
- Author
-
Johannesen KM, Gardella E, Encinas AC, Lehesjoki AE, Linnankivi T, Petersen MB, Lund ICB, Blichfeldt S, Miranda MJ, Pal DK, Lascelles K, Procopis P, Orsini A, Bonuccelli A, Giacomini T, Helbig I, Fenger CD, Sisodiya SM, Hernandez-Hernandez L, Krithika S, Rumple M, Masnada S, Valente M, Cereda C, Giordano L, Accorsi P, Bürki SE, Mancardi M, Korff C, Guerrini R, von Spiczak S, Hoffman-Zacharska D, Mazurczak T, Coppola A, Buono S, Vecchi M, Hammer MF, Varesio C, Veggiotti P, Lal D, Brünger T, Zara F, Striano P, Rubboli G, and Møller RS
- Subjects
- Anticonvulsants therapeutic use, Ataxia genetics, Child, Child, Preschool, Cognitive Dysfunction genetics, Electroencephalography, Epilepsy drug therapy, Epilepsy physiopathology, Genetic Testing, High-Throughput Nucleotide Sequencing, Humans, Infant, Intellectual Disability genetics, Language Development Disorders genetics, Movement Disorders genetics, Muscle Hypotonia genetics, Pedigree, Severity of Illness Index, Epilepsy genetics, Mutation, Missense, NAV1.6 Voltage-Gated Sodium Channel genetics
- Abstract
Objective: Pathogenic variants in SCN8A have been associated with a wide spectrum of epilepsy phenotypes, ranging from benign familial infantile seizures (BFIS) to epileptic encephalopathies with variable severity. Furthermore, a few patients with intellectual disability (ID) or movement disorders without epilepsy have been reported. The vast majority of the published SCN8A patients suffer from severe developmental and epileptic encephalopathy (DEE). In this study, we aimed to provide further insight on the spectrum of milder SCN8A-related epilepsies., Methods: A cohort of 1095 patients were screened using a next generation sequencing panel. Further patients were ascertained from a network of epilepsy genetics clinics. Patients with severe DEE and BFIS were excluded from the study., Results: We found 36 probands who presented with an SCN8A-related epilepsy and normal intellect (33%) or mild (61%) to moderate ID (6%). All patients presented with epilepsy between age 1.5 months and 7 years (mean = 13.6 months), and 58% of these became seizure-free, two-thirds on monotherapy. Neurological disturbances included ataxia (28%) and hypotonia (19%) as the most prominent features. Interictal electroencephalogram was normal in 41%. Several recurrent variants were observed, including Ile763Val, Val891Met, Gly1475Arg, Gly1483Lys, Phe1588Leu, Arg1617Gln, Ala1650Val/Thr, Arg1872Gln, and Asn1877Ser., Significance: With this study, we explore the electroclinical features of an intermediate SCN8A-related epilepsy with mild cognitive impairment, which is for the majority a treatable epilepsy., (Wiley Periodicals, Inc. © 2019 International League Against Epilepsy.)
- Published
- 2019
- Full Text
- View/download PDF
22. Genetic literacy series: Primer part 2-Paradigm shifts in epilepsy genetics.
- Author
-
Helbig I, Heinzen EL, and Mefford HC
- Subjects
- Databases, Genetic, Exome genetics, Genetic Testing, Humans, Infant, Male, Genetic Variation genetics, Spasms, Infantile genetics
- Abstract
This is the second of a 2-part primer on the genetics of the epilepsies within the Genetic Literacy Series of the Genetics Commission of the International League Against Epilepsy. In Part 1, we covered types of genetic variation, inheritance patterns, and their relationship to disease. In Part 2, we apply these basic principles to the case of a young boy with epileptic encephalopathy and ask 3 important questions: (1) Is the gene in question an established genetic etiology for epilepsy? (2) Is the variant in this particular gene pathogenic by established variant interpretation criteria? (3) Is the variant considered causative in the clinical context? These questions are considered and then answered for the clinical case in question., (Wiley Periodicals, Inc. © 2018 International League Against Epilepsy.)
- Published
- 2018
- Full Text
- View/download PDF
23. Commentary: The genetic architecture of the epilepsies, as told by 8500 gene panels.
- Author
-
Helbig I
- Subjects
- Humans, Neurodevelopmental Disorders genetics, Epilepsy genetics, Genetic Testing
- Published
- 2018
- Full Text
- View/download PDF
24. Defining the phenotypic spectrum of SLC6A1 mutations.
- Author
-
Johannesen KM, Gardella E, Linnankivi T, Courage C, de Saint Martin A, Lehesjoki AE, Mignot C, Afenjar A, Lesca G, Abi-Warde MT, Chelly J, Piton A, Merritt JL 2nd, Rodan LH, Tan WH, Bird LM, Nespeca M, Gleeson JG, Yoo Y, Choi M, Chae JH, Czapansky-Beilman D, Reichert SC, Pendziwiat M, Verhoeven JS, Schelhaas HJ, Devinsky O, Christensen J, Specchio N, Trivisano M, Weber YG, Nava C, Keren B, Doummar D, Schaefer E, Hopkins S, Dubbs H, Shaw JE, Pisani L, Myers CT, Tang S, Tang S, Pal DK, Millichap JJ, Carvill GL, Helbig KL, Mecarelli O, Striano P, Helbig I, Rubboli G, Mefford HC, and Møller RS
- Subjects
- Adolescent, Adult, Anticonvulsants therapeutic use, Ataxia complications, Ataxia genetics, Ataxia physiopathology, Child, Child, Preschool, Cohort Studies, Electroencephalography, Epilepsies, Myoclonic complications, Epilepsies, Myoclonic drug therapy, Epilepsies, Myoclonic genetics, Epilepsies, Partial complications, Epilepsies, Partial drug therapy, Epilepsies, Partial genetics, Epilepsies, Partial physiopathology, Epilepsy, Generalized complications, Epilepsy, Generalized drug therapy, Epilepsy, Generalized genetics, Epilepsy, Generalized physiopathology, Female, Genetic Association Studies, Humans, Intellectual Disability complications, Intellectual Disability genetics, Language Development Disorders complications, Language Development Disorders genetics, Male, Mutation, Mutation, Missense, Neurodevelopmental Disorders complications, Neurodevelopmental Disorders genetics, Phenotype, Treatment Outcome, Valproic Acid therapeutic use, Young Adult, Epilepsies, Myoclonic physiopathology, GABA Plasma Membrane Transport Proteins genetics, Intellectual Disability physiopathology, Language Development Disorders physiopathology
- Abstract
Objective: Pathogenic SLC6A1 variants were recently described in patients with myoclonic atonic epilepsy (MAE) and intellectual disability (ID). We set out to define the phenotypic spectrum in a larger cohort of SCL6A1-mutated patients., Methods: We collected 24 SLC6A1 probands and 6 affected family members. Four previously published cases were included for further electroclinical description. In total, we reviewed the electroclinical data of 34 subjects., Results: Cognitive development was impaired in 33/34 (97%) subjects; 28/34 had mild to moderate ID, with language impairment being the most common feature. Epilepsy was diagnosed in 31/34 cases with mean onset at 3.7 years. Cognitive assessment before epilepsy onset was available in 24/31 subjects and was normal in 25% (6/24), and consistent with mild ID in 46% (11/24) or moderate ID in 17% (4/24). Two patients had speech delay only, and 1 had severe ID. After epilepsy onset, cognition deteriorated in 46% (11/24) of cases. The most common seizure types were absence, myoclonic, and atonic seizures. Sixteen cases fulfilled the diagnostic criteria for MAE. Seven further patients had different forms of generalized epilepsy and 2 had focal epilepsy. Twenty of 31 patients became seizure-free, with valproic acid being the most effective drug. There was no clear-cut correlation between seizure control and cognitive outcome. Electroencephalography (EEG) findings were available in 27/31 patients showing irregular bursts of diffuse 2.5-3.5 Hz spikes/polyspikes-and-slow waves in 25/31. Two patients developed an EEG pattern resembling electrical status epilepticus during sleep. Ataxia was observed in 7/34 cases. We describe 7 truncating and 18 missense variants, including 4 recurrent variants (Gly232Val, Ala288Val, Val342Met, and Gly362Arg)., Significance: Most patients carrying pathogenic SLC6A1 variants have an MAE phenotype with language delay and mild/moderate ID before epilepsy onset. However, ID alone or associated with focal epilepsy can also be observed., (Wiley Periodicals, Inc. © 2018 International League Against Epilepsy.)
- Published
- 2018
- Full Text
- View/download PDF
25. Primer Part 1-The building blocks of epilepsy genetics.
- Author
-
Helbig I, Heinzen EL, and Mefford HC
- Subjects
- Epilepsy epidemiology, Epilepsy history, Genetic Predisposition to Disease, Genetic Variation genetics, History, 20th Century, Humans, Epilepsy genetics, Molecular Epidemiology history
- Abstract
This is the first of a two-part primer on the genetics of the epilepsies within the Genetic Literacy Series of the Genetics Commission of the International League Against Epilepsy. In Part 1, we cover the foundations of epilepsy genetics including genetic epidemiology and the range of genetic variants that can affect the risk for developing epilepsy. We discuss various epidemiologic study designs that have been applied to the genetics of the epilepsies including population studies, which provide compelling evidence for a strong genetic contribution in many epilepsies. We discuss genetic risk factors varying in size, frequency, inheritance pattern, effect size, and phenotypic specificity, and provide examples of how genetic risk factors within the various categories increase the risk for epilepsy. We end by highlighting trends in epilepsy genetics including the increasing use of massive parallel sequencing technologies., (Wiley Periodicals, Inc. © 2016 International League Against Epilepsy.)
- Published
- 2016
- Full Text
- View/download PDF
26. Seizures as presenting and prominent symptom in chorea-acanthocytosis with c.2343del VPS13A gene mutation.
- Author
-
Benninger F, Afawi Z, Korczyn AD, Oliver KL, Pendziwiat M, Nakamura M, Sano A, Helbig I, Berkovic SF, and Blatt I
- Subjects
- Adolescent, Adult, Diagnosis, Differential, Electroencephalography methods, Female, Humans, Magnetic Resonance Imaging methods, Male, Neuroacanthocytosis complications, Pedigree, Seizures etiology, Young Adult, Mutation genetics, Neuroacanthocytosis diagnosis, Neuroacanthocytosis genetics, Seizures diagnosis, Seizures genetics, Vesicular Transport Proteins genetics
- Abstract
Objective: The aim of the study was to characterize the clinical features of nine patients in three families with chorea-acanthocytosis (ChAc) sharing the same rare c.2343del mutation in the VPS13A gene., Methods: Genetic test results, clinical description, magnetic resonance imaging (MRI), and electroencephalography (EEG), as well as laboratory results are summarized., Results: ChAc is a rare genetic disorder characterized by hyperkinetic movements, seizures, cognitive decline, neuropsychiatric symptoms, and acanthocytes on peripheral blood smear. This unique cohort of nine patients is characterized by seizures as a first and prominent symptom. In our patients, other features of ChAc appeared later, including tics, other movement disorders, dysarthria, and mild to moderate cognitive decline., Significance: Patients with chorea-acanthocytosis carrying the described rare mutation can present with focal, treatment-resistant seizures., (Wiley Periodicals, Inc. © 2016 International League Against Epilepsy.)
- Published
- 2016
- Full Text
- View/download PDF
27. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome.
- Author
-
Larsen J, Johannesen KM, Ek J, Tang S, Marini C, Blichfeldt S, Kibaek M, von Spiczak S, Weckhuysen S, Frangu M, Neubauer BA, Uldall P, Striano P, Zara F, Kleiss R, Simpson M, Muhle H, Nikanorova M, Jepsen B, Tommerup N, Stephani U, Guerrini R, Duno M, Hjalgrim H, Pal D, Helbig I, and Møller RS
- Subjects
- Carbohydrate Metabolism, Inborn Errors genetics, Child, Preschool, Denmark epidemiology, Epilepsy, Generalized genetics, Glucose Transporter Type 1 deficiency, Glucose Transporter Type 1 physiology, Humans, Infant, Monosaccharide Transport Proteins genetics, Mutation, Syndrome, Carbohydrate Metabolism, Inborn Errors epidemiology, Epilepsies, Myoclonic genetics, Epilepsy, Absence genetics, Glucose Transporter Type 1 genetics, Monosaccharide Transport Proteins deficiency
- Abstract
The first mutations identified in SLC2A1, encoding the glucose transporter type 1 (GLUT1) protein of the blood-brain barrier, were associated with severe epileptic encephalopathy. Recently, dominant SLC2A1 mutations were found in rare autosomal dominant families with various forms of epilepsy including early onset absence epilepsy (EOAE), myoclonic astatic epilepsy (MAE), and genetic generalized epilepsy (GGE). Our study aimed to investigate the possible role of SLC2A1 in various forms of epilepsy including MAE and absence epilepsy with early onset. We also aimed to estimate the frequency of GLUT1 deficiency syndrome in the Danish population. One hundred twenty patients with MAE, 50 patients with absence epilepsy, and 37 patients with unselected epilepsies, intellectual disability (ID), and/or various movement disorders were screened for mutations in SLC2A1. Mutations in SLC2A1 were detected in 5 (10%) of 50 patients with absence epilepsy, and in one (2.7%) of 37 patient with unselected epilepsies, ID, and/or various movement disorders. None of the 120 MAE patients harbored SLC2A1 mutations. We estimated the frequency of SLC2A1 mutations in the Danish population to be approximately 1:83,000. Our study confirmed the role of SLC2A1 mutations in absence epilepsy with early onset. However, our study failed to support the notion that SLC2A1 aberrations are a cause of MAE without associated features such as movement disorders., (Wiley Periodicals, Inc. © 2015 International League Against Epilepsy.)
- Published
- 2015
- Full Text
- View/download PDF
28. Investigating the genetic basis of fever-associated syndromic epilepsies using copy number variation analysis.
- Author
-
Hartmann C, von Spiczak S, Suls A, Weckhuysen S, Buyse G, Vilain C, Van Bogaert P, De Jonghe P, Cook J, Muhle H, Stephani U, Helbig I, and Mefford HC
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Chromosome Aberrations, Chromosome Deletion, Comparative Genomic Hybridization, Female, Genetic Association Studies, Humans, Male, Middle Aged, Phenotype, Young Adult, DNA Copy Number Variations genetics, Epilepsy etiology, Epilepsy genetics, Fever complications, NAV1.1 Voltage-Gated Sodium Channel genetics
- Abstract
Fever-associated syndromic epilepsies ranging from febrile seizures plus (FS+) to Dravet syndrome have a significant genetic component. However, apart from SCN1A mutations in >80% of patients with Dravet syndrome, the genetic underpinnings of these epilepsies remain largely unknown. Therefore, we performed a genome-wide screening for copy number variations (CNVs) in 36 patients with SCN1A-negative fever-associated syndromic epilepsies. Phenotypes included Dravet syndrome (n = 23; 64%), genetic epilepsy with febrile seizures plus (GEFS+) and febrile seizures plus (FS+) (n = 11; 31%) and unclassified fever-associated epilepsies (n = 2; 6%). Array comparative genomic hybridization (CGH) was performed using Agilent 4 × 180K arrays. We identified 13 rare CNVs in 8 (22%) of 36 individuals. These included known pathogenic CNVs in 4 (11%) of 36 patients: a 1q21.1 duplication in a proband with Dravet syndrome, a 14q23.3 deletion in a proband with FS+, and two deletions at 16p11.2 and 1q44 in two individuals with fever-associated epilepsy with concomitant autism and/or intellectual disability. In addition, a 3q13.11 duplication in a patient with FS+ and two de novo duplications at 7p14.2 and 18q12.2 in a patient with atypical Dravet syndrome were classified as likely pathogenic. Six CNVs were of unknown significance. The identified genomic aberrations overlap with known neurodevelopmental disorders, suggesting that fever-associated epilepsy syndromes may be a recurrent clinical presentation of known microdeletion syndromes., (Wiley Periodicals, Inc. © 2015 International League Against Epilepsy.)
- Published
- 2015
- Full Text
- View/download PDF
29. Commentary: Pathogenic EFHC1 mutations are tolerated in healthy individuals dependent on reported ancestry.
- Author
-
Pal D and Helbig I
- Subjects
- Humans, Calcium-Binding Proteins genetics, Epilepsy, Generalized genetics, Genetic Predisposition to Disease, Mutation genetics, Myoclonic Epilepsy, Juvenile genetics
- Published
- 2015
- Full Text
- View/download PDF
30. Variability of EEG-fMRI findings in patients with SCN1A-positive Dravet syndrome.
- Author
-
Moehring J, von Spiczak S, Moeller F, Helbig I, Wolff S, Jansen O, Muhle H, Boor R, Stephani U, and Siniatchkin M
- Subjects
- Adolescent, Adult, Brain Mapping, Child, Child, Preschool, Epilepsies, Myoclonic physiopathology, Female, Humans, Image Processing, Computer-Assisted, Male, Oxygen blood, Young Adult, Brain blood supply, Brain physiopathology, Electroencephalography, Epilepsies, Myoclonic genetics, Epilepsies, Myoclonic pathology, Magnetic Resonance Imaging, NAV1.1 Voltage-Gated Sodium Channel genetics
- Abstract
Purpose: Dravet syndrome (DS) or severe myoclonic epilepsy of infancy is an intractable epileptic encephalopathy of early childhood that is caused by a mutation in the SCN1A gene in most patients. The aim of this study was to identify a syndrome-specific epileptic network underlying interictal epileptiform discharges (IEDs) in patients with DS., Methods: Ten patients with the diagnosis of DS associated with mutations in the SCN1A gene were investigated using simultaneous recording of electroencephalography and functional magnetic resonance imaging ((EEG-fMRI). Time series of IEDs were used as regressors for the statistical fMRI analysis., Key Findings: In nine patients with DS, individual blood oxygenation level-dependent (BOLD) signal changes were seen. In three patients the thalamus was involved. Furthermore, regions of the default mode network were activated in seven patients. However, a common activation pattern associated with IEDs could not be detected., Significance: The study demonstrates that, despite a common genetic etiology in DS, different neuronal networks underlie the individual IEDs., (Wiley Periodicals, Inc. © 2013 International League Against Epilepsy.)
- Published
- 2013
- Full Text
- View/download PDF
31. Reduction of seizure frequency after epilepsy surgery in a patient with STXBP1 encephalopathy and clinical description of six novel mutation carriers.
- Author
-
Weckhuysen S, Holmgren P, Hendrickx R, Jansen AC, Hasaerts D, Dielman C, de Bellescize J, Boutry-Kryza N, Lesca G, Von Spiczak S, Helbig I, Gill D, Yendle S, Møller RS, Klitten L, Korff C, Godfraind C, Van Rijckevorsel K, De Jonghe P, Hjalgrim H, Scheffer IE, and Suls A
- Subjects
- Brain metabolism, Brain pathology, Child, Child, Preschool, Electroencephalography, Female, Humans, Infant, Male, Phosphopyruvate Hydratase metabolism, Seizures etiology, Seizures pathology, Spasms, Infantile complications, Young Adult, Genetic Predisposition to Disease genetics, Munc18 Proteins genetics, Mutation genetics, Seizures genetics, Seizures surgery, Spasms, Infantile genetics
- Abstract
Mutations in STXBP1 have been identified in a subset of patients with early onset epileptic encephalopathy (EE), but the full phenotypic spectrum remains to be delineated. Therefore, we screened a cohort of 160 patients with an unexplained EE, including patients with early myoclonic encephalopathy (EME), Ohtahara syndrome, West syndrome, nonsyndromic EE with onset in the first year, and Lennox-Gastaut syndrome (LGS). We found six de novo mutations in six patients presenting as Ohtahara syndrome (2/6, 33%), West syndrome (1/65, 2%), and nonsyndromic early onset EE (3/64, 5%). No mutations were found in LGS or EME. Only two of four mutation carriers with neonatal seizures had Ohtahara syndrome. Epileptic spasms were present in five of six patients. One patient with normal magnetic resonance imaging (MRI) but focal seizures underwent epilepsy surgery and seizure frequency dropped drastically. Neuropathology showed a focal cortical dysplasia type 1a. There is a need for additional neuropathologic studies to explore whether STXBP1 mutations can lead to structural brain abnormalities., (Wiley Periodicals, Inc. © 2013 International League Against Epilepsy.)
- Published
- 2013
- Full Text
- View/download PDF
32. Exon-disrupting deletions of NRXN1 in idiopathic generalized epilepsy.
- Author
-
Møller RS, Weber YG, Klitten LL, Trucks H, Muhle H, Kunz WS, Mefford HC, Franke A, Kautza M, Wolf P, Dennig D, Schreiber S, Rückert IM, Wichmann HE, Ernst JP, Schurmann C, Grabe HJ, Tommerup N, Stephani U, Lerche H, Hjalgrim H, Helbig I, and Sander T
- Subjects
- Adult, Age of Onset, Anticonvulsants therapeutic use, Calcium-Binding Proteins, Case-Control Studies, DNA Copy Number Variations, Electroencephalography, Epilepsy, Generalized drug therapy, Epilepsy, Generalized psychology, Family, Female, Fructose analogs & derivatives, Fructose therapeutic use, Gene Deletion, Genotype, Humans, Infant, Lamotrigine, Male, Microarray Analysis, Middle Aged, Neural Cell Adhesion Molecules, Neuropsychological Tests, Odds Ratio, Pedigree, Topiramate, Triazines therapeutic use, Valproic Acid therapeutic use, Cell Adhesion Molecules, Neuronal genetics, Epilepsy, Generalized genetics, Exons genetics, Nerve Tissue Proteins genetics
- Abstract
Purpose: Neurexins are neuronal adhesion molecules located in the presynaptic terminal, where they interact with postsynaptic neuroligins to form a transsynaptic complex required for efficient neurotransmission in the brain. Recently, deletions and point mutations of the neurexin 1 (NRXN1) gene have been associated with a broad spectrum of neuropsychiatric disorders. This study aimed to investigate if NRXN1 deletions also increase the risk of idiopathic generalized epilepsies (IGEs)., Methods: We screened for deletions involving the NRXN1 gene in 1,569 patients with IGE and 6,201 controls using high-density oligonucleotide microarrays., Key Findings: We identified exon-disrupting deletions of NRXN1 in 5 of 1,569 patients with IGE and 2 of 6,201 control individuals (p = 0.0049; odds ratio (OR) 9.91, 95% confidence interval (CI) 1.92-51.12). A complex familial segregation pattern in the IGE families was observed, suggesting that heterozygous NRXN1 deletions are susceptibility variants. Intriguingly, we identified a second large copy number variant in three of five index patients, supporting an involvement of heterogeneous susceptibility alleles in the etiology of IGE., Significance: We conclude that exon-disrupting deletions of NRXN1 represent a genetic risk factor in the genetically complex predisposition of common IGE syndromes., (Wiley Periodicals, Inc. © 2012 International League Against Epilepsy.)
- Published
- 2013
- Full Text
- View/download PDF
33. Absence seizures with intellectual disability as a phenotype of the 15q13.3 microdeletion syndrome.
- Author
-
Muhle H, Mefford HC, Obermeier T, von Spiczak S, Eichler EE, Stephani U, Sander T, and Helbig I
- Subjects
- Adolescent, Adult, Cohort Studies, Electroencephalography, Female, Genetic Testing, Humans, Magnetic Resonance Imaging, Male, Nucleic Acid Hybridization, Pedigree, Young Adult, Chromosome Aberrations, Chromosome Deletion, Chromosomes, Human, Pair 15 genetics, Epilepsy, Absence complications, Intellectual Disability complications, Intellectual Disability genetics
- Abstract
15q13.3 microdeletions are the most common genetic findings identified in idiopathic generalized epilepsies to date, and they are present in up to 1% of patients. In addition, 15q13.3 microdeletions have been described in patients with epilepsy as part of a complex neurodevelopmental phenotype. We analyzed a cohort of 570 patients with various pediatric epilepsies for 15q13.3 microdeletions. Screening was performed using quantitative polymerase chain reaction; deletions were confirmed by array comparative genomic hybridization (CGH). We carried out detailed phenotyping of deletion carriers. In total, we identified four pediatric patients with 15q13.3 microdeletions, including one previously described patient. Two of four deletions were de novo, one deletion was inherited from an unaffected parent, and for one patient the inheritance is unknown. All four patients had absence epilepsy with various degrees of intellectual disability. We suggest that absence epilepsy accompanied by intellectual disability may represent a common phenotype of the 15q13.3 microdeletion in pediatric patients with epilepsy., (Wiley Periodicals, Inc. © 2011 International League Against Epilepsy.)
- Published
- 2011
- Full Text
- View/download PDF
34. Comprehensive analysis of candidate genes for photosensitivity using a complementary bioinformatic and experimental approach.
- Author
-
von Spiczak S, Finsterwalder K, Muhle H, Franke A, Schilhabel M, Stephani U, and Helbig I
- Subjects
- Computational Biology methods, Genes genetics, Genetic Loci genetics, Genetic Markers genetics, Humans, Polymorphism, Single Nucleotide genetics, Receptors, N-Methyl-D-Aspartate genetics, Sequence Analysis, DNA, Epilepsy, Reflex genetics, Genetic Association Studies
- Abstract
Photoparoxysmal response (PPR) is a highly heritable electroencephalographic trait characterized by an increased sensitivity to photic stimulation. It may serve as an endophenotype for idiopathic generalized epilepsy. Family linkage studies identified susceptibility loci for PPR on chromosomes 5q35.3, 8q21.13, and 16p13.3. This study aimed to identify key candidate genes within these loci. We used bioinformatics tools for gene prioritization integrating information on biologic function, sequence data, gene expression, and others. The prime candidate gene from this analysis was sequenced in 48 photopositive probands. Presumed functional implications of identified polymorphisms were investigated using bioinformatics methods. The glutamate receptor subunit gene GRIN2A was identified as a prime candidate gene. Sequence analysis revealed various new polymorphisms. None of the identified variants was predicted to be functionally relevant. We objectified the selection of candidate genes for PPR without an a priori hypothesis. Particularly among the various ion channel genes in the linkage regions, GRIN2A was identified as the prime candidate gene. GRIN2A mutations have recently been identified in various epilepsies. Even though our mutation analysis failed to demonstrate direct involvement of GRIN2A in photosensitivity, in silico gene prioritization may provide a useful tool for the identification of candidate genes within large genomic regions., (Wiley Periodicals, Inc. © 2011 International League Against Epilepsy.)
- Published
- 2011
- Full Text
- View/download PDF
35. A retrospective population-based study on seizures related to childhood vaccination.
- Author
-
von Spiczak S, Helbig I, Drechsel-Baeuerle U, Muhle H, van Baalen A, van Kempen MJ, Lindhout D, Scheffer IE, Berkovic SF, Stephani U, and Keller-Stanislawski B
- Subjects
- Child, Child, Preschool, Cohort Studies, Epilepsy classification, Epilepsy etiology, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Population Surveillance, Retrospective Studies, Seizures classification, Syndrome, Seizures etiology, Vaccination adverse effects
- Abstract
Purpose: Cases of severe childhood epilepsies in temporal association with vaccination have great impact on the acceptance of vaccination programs by parents and health care providers. However, little is known about the type and frequency of seizures and epilepsy syndromes following vaccination. This study aims to describe the clinical features of children presenting with seizures after vaccination using a register-based cohort., Methods: We surveyed the national German database of adverse events following immunization (AEFI) for reported seizures and epilepsies in children aged 0-6 years. All cases reported in 2006-2008 were analyzed retrospectively; available clinical information was reevaluated and classified by seizure type and epilepsy syndrome., Key Findings: In total, 328 cases reported between 2006 and 2008 were included. Data supportive of seizures or epilepsy were present in 247 (75.3%) of 328 patients with a mean interval between the vaccination and the epileptic event of 24 h and 7.5 days for inactivated and attenuated vaccines, respectively. Fifty-one (15.5%) of 328 patients presented with syncope, hypotonic-hyporesponsive episodes, or other nonepileptic events. Information was insufficient for classification into epileptic versus nonepileptic events in 30 (11.3%) of 328 patients. For cases with confirmed seizures, febrile seizures were present in 121 (49%) of 247 cases, and 38 (15.4%) of 247 patients had single afebrile seizures. Status epilepticus was described in 21 (8.5%) of 247 patients. Thirty-one (12.6%) of 247 patients presented with various pediatric epilepsy syndromes. Severe childhood epilepsies (Dravet syndrome, West syndrome, Lennox-Gastaut syndrome, or Doose syndrome) were diagnosed in 29 (11.7%) of 247 patients, with the vaccination-associated event being the first documented seizure in 15 (51.7%) of 29 patients., Significance: Vaccination-associated seizures present in the setting of various epilepsy syndromes, including severe childhood epilepsies in >10% of cases. Early diagnosis of the corresponding epilepsy syndromes and confirmation of an underlying etiology is important for treatment decisions, genetic counseling, and public health evaluation of vaccine safety., (Wiley Periodicals, Inc. © 2011 International League Against Epilepsy.)
- Published
- 2011
- Full Text
- View/download PDF
36. A retrospective study of the relation between vaccination and occurrence of seizures in Dravet syndrome.
- Author
-
Tro-Baumann B, von Spiczak S, Lotte J, Bast T, Haberlandt E, Sassen R, Freund A, Leiz S, Stephani U, Boor R, Holthausen H, Helbig I, and Kluger G
- Subjects
- Adolescent, Child, Child, Preschool, Diphtheria-Tetanus-Pertussis Vaccine adverse effects, Epilepsies, Myoclonic complications, Epilepsies, Myoclonic genetics, Humans, Incidence, Infant, Mutation genetics, NAV1.1 Voltage-Gated Sodium Channel, Nerve Tissue Proteins genetics, Retrospective Studies, Seizures etiology, Seizures genetics, Sodium Channels genetics, Syndrome, Young Adult, Epilepsies, Myoclonic epidemiology, Seizures epidemiology, Vaccination adverse effects
- Abstract
Dravet syndrome is a severe epileptic encephalopathy starting in the first year of life. Mutations in SCN1A can be identified in the majority of patients, and epileptic seizures in the setting of fever are a clinical hallmark. Fever is also commonly seen after vaccinations and provocation of epileptic seizures by vaccinations in patients with Dravet syndrome has been reported, but not systematically assessed. In a retrospective evaluation of 70 patients with Dravet syndrome and SCN1A mutations, seizures following vaccinations were reported in 27%. In 58% of these patients vaccination-related seizures represented the first clinical manifestation. The majority of seizures occurred after DPT vaccinations and within 72 h after vaccination. Two-thirds of events occurred in the context of fever. Our findings highlight seizures after vaccinations as a common feature in Dravet syndrome and emphasize the need for preventive measures for seizures triggered by vaccination or fever in these children., (Wiley Periodicals, Inc. © 2010 International League Against Epilepsy.)
- Published
- 2011
- Full Text
- View/download PDF
37. A duplication in 1q21.3 in a family with early onset and childhood absence epilepsy.
- Author
-
Muhle H, Steinich I, von Spiczak S, Franke A, Weber Y, Lerche H, Wittig M, Heidemann S, Suls A, de Jonghe P, Marini C, Guerrini R, Scheffer IE, Berkovic SF, Stephani U, Siebert R, Sander T, Helbig I, and Tönnies H
- Subjects
- Adenosine Deaminase genetics, Adolescent, Epilepsy, Absence diagnosis, Epilepsy, Generalized genetics, Family, Female, Humans, Male, Pedigree, RNA-Binding Proteins, Receptors, Nicotinic genetics, Chromosomes, Human, Pair 1 genetics, Epilepsy, Absence genetics, Gene Duplication genetics
- Abstract
Early onset absence epilepsy (EOAE) starting before the age of 4 years constitutes a rare subgroup of the idiopathic generalized epilepsies (IGEs). A strong genetic component in IGE has been suggested by twin and family studies. We describe a boy with absence seizures starting at the age of 9 months whose parents both had childhood absence epilepsy. A 192-kb duplication in 1q21.3 was identified in the proband and his father, encompassing the gene CHRNB2 coding for the β-2 subunit of the nicotinic acetylcholine receptor and the gene ADAR coding for adenosine deaminase, an enzyme responsible for RNA editing. Both are candidate genes for seizure disorders. The duplication was not identified in 191 independent IGE patients (93 EOAE; 98 classical IGE) or in 1,157 population controls., (Wiley Periodicals, Inc. © 2010 International League Against Epilepsy.)
- Published
- 2010
- Full Text
- View/download PDF
38. Genetic risk perception and reproductive decision making among people with epilepsy.
- Author
-
Helbig KL, Bernhardt BA, Conway LJ, Valverde KD, Helbig I, and Sperling MR
- Subjects
- Adult, Attitude to Health, Child of Impaired Parents statistics & numerical data, Epilepsy epidemiology, Female, Genetic Counseling, Humans, Infant, Newborn, Male, Pregnancy, Probability, Risk Assessment, Risk Factors, Surveys and Questionnaires, Decision Making, Epilepsy genetics, Epilepsy psychology, Genetic Predisposition to Disease psychology, Reproductive Behavior psychology
- Abstract
We investigated estimated offspring risk among people with epilepsy and factors important in the family-planning process. Data were collected for 88 participants using a questionnaire assessing perceived risk of offspring to develop epilepsy, importance of factors in the reproductive decision-making process, decision to have fewer children, and association between risk perception and family planning decisions. Thirty-four percent of participants had fewer children because of their epilepsy. Concerns about the ability to care for a child (p < 0.0001) and passing epilepsy onto a child (p = 0.003) were associated with the decision to have fewer children. The mean estimated risk of offspring to develop epilepsy was 26%, a 4-fold increase over estimated population risks. Genetic counseling may be beneficial for people with epilepsy, given the considerable overestimation of offspring risk.
- Published
- 2010
- Full Text
- View/download PDF
39. Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region.
- Author
-
Reutlinger C, Helbig I, Gawelczyk B, Subero JI, Tönnies H, Muhle H, Finsterwalder K, Vermeer S, Pfundt R, Sperner J, Stefanova I, Gillessen-Kaesbach G, von Spiczak S, van Baalen A, Boor R, Siebert R, Stephani U, and Caliebe A
- Subjects
- Adult, Age of Onset, Child, Electroencephalography statistics & numerical data, Epilepsies, Partial genetics, Humans, Landau-Kleffner Syndrome genetics, Phenotype, Receptors, Glutamate genetics, Receptors, N-Methyl-D-Aspartate genetics, Status Epilepticus genetics, Syndrome, Abnormalities, Multiple genetics, Chromosomes, Human, Pair 16 genetics, Epilepsy genetics, Epilepsy, Rolandic genetics, Intellectual Disability genetics, Sequence Deletion genetics
- Abstract
Seizure disorders of the rolandic region comprise a spectrum of different epilepsy syndromes ranging from benign rolandic epilepsy to more severe seizure disorders including atypical benign partial epilepsy/pseudo-Lennox syndrome,electrical status epilepticus during sleep, and Landau-Kleffner syndrome. Centrotemporal spikes are the unifying electroencephalographic hallmark of these benign focal epilepsies, indicating a pathophysiologic relationship between the various epilepsies arising from the rolandic region. The etiology of these epilepsies is elusive, but a genetic component is assumed given the heritability of the characteristic electrographic trait. Herein we report on three patients with intellectual disability, various dysmorphic features, and epilepsies involving the rolandic region, carrying previously undescribed deletions in 16p13. The only gene located in the critical region shared by all three patients is GRIN2A coding for the alpha-2 subunit of the neuronal N-methyl-D-aspartate(NMDA) receptor.
- Published
- 2010
- Full Text
- View/download PDF
40. Gene expression analysis in absence epilepsy using a monozygotic twin design.
- Author
-
Helbig I, Matigian NA, Vadlamudi L, Lawrence KM, Bayly MA, Bain SM, Diyagama D, Scheffer IE, Mulley JC, Holloway AJ, Dibbens LM, Berkovic SF, and Hayward NK
- Subjects
- Adult, Anticonvulsants therapeutic use, Cell Line, Tumor pathology, Epilepsy, Absence drug therapy, Female, Humans, Male, Oligonucleotide Array Sequence Analysis methods, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Reverse Transcriptase Polymerase Chain Reaction, Valproic Acid therapeutic use, Calcium-Binding Proteins genetics, Early Growth Response Protein 1 genetics, Epilepsy, Absence diagnosis, Epilepsy, Absence genetics, Gene Expression genetics, Twins, Monozygotic genetics
- Abstract
Purpose: To identify genes involved in idiopathic absence epilepsies by analyzing gene expression using a monozygotic (MZ) twin design., Methods: Genome-wide gene expression in lymphoblastoid cell lines (LCLs) was determined using microarrays derived from five discordant and four concordant MZ twin pairs with idiopathic absence epilepsies and five unaffected MZ twin pairs. Gene expression was analyzed using three strategies: discordant MZ twins were compared as matched pairs, MZ twins concordant for epilepsy were compared to control MZ twins, and a singleton design of affected versus unaffected MZ twin individuals was used irrespective of twin pairing. An overlapping gene list was generated from these analyses. Dysregulation of genes recognized from the microarray experiment was validated using quantitative real time PCR (qRT-PCR) in the twin sample and in an independent sample of 18 sporadic absence cases and 24 healthy controls., Results: Sixty-five probe sets were identified from the three combined microarray analysis strategies. Sixteen genes were chosen for validation and nine of these genes confirmed by qRT-PCR in the twin sample. Differential expression for EGR1 (an immediate early gene) and RCN2 (coding for the calcium-binding protein Reticulocalbin 2) were reconfirmed by qRT-PCR in the independent sample., Discussion: Using a unique sample of discordant MZ twins, our study identified genes with altered expression, which suggests novel mechanisms in idiopathic absence epilepsy. Dysregulation of EGR1 and RCN2 is implicated in idiopathic absence epilepsy.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.